On November 11, HeartFlow Inc saw an Intraday Rise of 4.27% in Regular Trading, trading at $58.2 with turnover of $16.8979 million.
The most direct catalyst available is a same-day market alert highlighting investor focus ahead of the company’s November 12 post-market earnings report, alongside recently released clinical updates that reinforced the commercial outlook for its AI-based coronary disease platform.
Consensus cited in the earnings preview points to quarterly revenue of about $65.26 million, up 55.54% year over year, after the prior quarter delivered $64.08 million of revenue, 47.57% growth, 83.00% gross margin, and adjusted EPS of negative $0.07, with losses narrowing materially. Separately, recent DECIDE registry data linked HeartFlow Plaque Analysis to 34% fewer major cardiovascular events and roughly half the heart attack rate at one year, while the 1,105-patient P4 trial met its primary endpoint and showed CT-guided PCI planning was non-inferior to IVUS with better procedural efficiency.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments